Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Preclinical Models of Multiple Sclerosis: Advantages and Limitations towards Better Therapies.
A rare case of nonenhancing primary central nervous system lymphoma mimic multiple sclerosis.
5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly¬(ADP Ribose)¬Polymerases (PARPs).
Comparison of Compliance And Discontinuation Rates Among Ms Patients Treated With Fingolimod and Other Disease-Modifying Therapies: A Canadian Retrospective Claims Analysis.
Multiple sclerosis in a postgraduate student of anaesthesia: illness in doctors and fitness to practice.
Downmodulation of peripheral MOG-specific immunity by pVAXhsp65 treatment during EAE does not reach the CNS.
Microglia-derived IL-1β triggers p53-mediated cell cycle arrest and apoptosis in neural precursor cells.
[Disease-modifying drugs in pediatric patients with multiple sclerosis].
Increased Concentrations of Interleukin-33 in the Serum and Cerebrospinal Fluid of Patients with Multiple Sclerosis.
A Novel Asp121Asn Mutation of Myelin Protein Zero Is Associated with Late-Onset Axonal Charcot-Marie-Tooth Disease, Hearing Loss and Pupil Abnormalities.
Disability profile of multiple sclerosis in New Zealand.
Modulation of oligodendrocyte differentiation and maturation by combined biochemical and mechanical cues.
Neuroinflammation: A common denominator for stroke, multiple sclerosis and Alzheimer's disease.
Functional connectivity changes within specific networks parallel the clinical evolution of multiple sclerosis.
Investigating Tissue Optical Properties and Texture Descriptors of the Retina in Patients with Multiple Sclerosis.
Hilbert-Huang transform based instrumental assessment of intention tremor in multiple sclerosis.
The natural dual cyclooxygenase and 5-lipoxygenase inhibitor flavocoxid is protective in EAE through effects on Th1/Th17 differentiation and macrophage/microglia activation.
Adipocytokine Profile, Cytokine Levels and Foxp3 Expression in Multiple Sclerosis: a Possible Link to Susceptibility and Clinical Course of Disease.
Hypothalamic abnormality in patients with inflammatory demyelinating disorders.
Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis.
Autopsy-proven demyelination associated with infliximab treatment.
Patient-specific early classification of multivariate observations.
Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.
Grb2 Is Important for T Cell Development, Th Cell Differentiation, and Induction of Experimental Autoimmune Encephalomyelitis.
Palmoplantar Keratoderma and Charcot-Marie-Tooth: combination of two independent genetic diseases? Identification of two point mutations in CMT2 and PPK genes by whole exome sequencing.
Pages
« first
‹ previous
…
665
666
667
668
669
670
671
672
673
…
next ›
last »